Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Vittorio Fusco, Giuseppina Campisi, Paul de Boissieu, Federico Monaco, Anna Baraldi, Gianmauro Numico, Alberto Bedogni
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI AG 2018-09-01
Serie:Dentistry Journal
Soggetti:
osteonecrosis of the jaw
ONJ
osteonecrosis
jaw
medication-related osteonecrosis of the jaw
MRONJ
multiple myeloma
denosumab
zoledronic acid
Accesso online:http://www.mdpi.com/2304-6767/6/3/42
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi